首页> 外文期刊>Pediatric blood & cancer >The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.
【24h】

The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan.

机译:造血干细胞移植在复发性或原发性难治性儿童B细胞非霍奇金淋巴瘤与成熟B细胞白血病中的作用:对日本入组病例的回顾性分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: There have been excellent treatment results for children with B-cell non-Hodgkin lymphoma (B-NHL) and mature B-cell leukemia (B-ALL) in the last few decades. However, a small subset of relapsed or refractory patients, after first-line therapy, still have a poor prognosis. PROCEDURE: Thirty-three patients with relapsed or primary refractory B-NHL/B-ALL among 327 newly diagnosed patients between 1996 and 2004 were analyzed retrospectively. RESULTS: After salvage therapy, 18 patients were chemotherapy-sensitive and 15 patients suffered from progression. Among 18 patients who had a chemotherapy-sensitive disease, 4 of 5 patients who underwent hematopoietic stem cell transplantation (HSCT) during remission survived without progression, while 3 of 12 patients who did not receive HSCT were alive without disease progression. Fifteen patients never sensitive to salvage therapy died. CONCLUSIONS: Patients with relapsed/primary refractory B-NHL/B-ALL have a poor prognosis with current treatment approaches, while the patients sensitive to salvage therapy have a respectable chance to achieve a sustained complete second remission with HSCT.
机译:背景:在过去的几十年中,对于患有B细胞非霍奇金淋巴瘤(B-NHL)和成熟B细胞白血病(B-ALL)的儿童取得了出色的治疗效果。然而,一线治疗后,一小部分复发或难治性患者的预后仍然很差。程序:回顾性分析1996年至2004年之间327例新诊断的33例复发或原发性难治性B-NHL / B-ALL患者。结果:挽救治疗后,18例对化疗敏感,15例进展。在18位患有化疗敏感性疾病的患者中,缓解期间接受造血干细胞移植(HSCT)的5位患者中有4位存活下来,但没有进展,而未接受HSCT的12位患者中有3位没有疾病进展。从未对挽救疗法敏感的15名患者死亡。结论:复发/原发性难治性B-NHL / B-ALL患者在目前的治疗方法中预后较差,而对挽救疗法敏感的患者则有相当大的机会通过HSCT实现持续的完全第二次缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号